Guillaume E Courtoy

Dr. Guillaume E Courtoy

Experimental Pathology, Vrije Universiteit Brussel, Brussels, Brussels-Capital Region, Belgium
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
ILIsabelle A. Leclercq
Isabelle A. Leclercq
AFAntoine Froidure
Antoine Froidure
GSGuglielmo Schiano
Guglielmo Schiano
JMJohann Morelle
Johann Morelle
Caroline BouzinCaroline Bouzin
Caroline Bouzin
Current understanding of fibrosis remains incomplete despite the increasing burden of related diseases. Preclinical models are used to dissect the pathogenesis and dynamics of fibrosis, and to evaluate anti-fibrotic therapies. These studies require objective and accurate measurements of fibrosis. Existing histological quantification methods are operator-dependent, organ-specific, and/or need advanced equipment. Therefore, we developed a robust, minimally operator-dependent, and tissue-transposable digital method for fibrosis quantification. The proposed method involves a novel algorithm for more specific and more sensitive detection of collagen fibers stained by picrosirius red (PSR), a computer-assisted segmentation of histological structures, and a new automated morphological classification of fibers according to their compactness. The new algorithm proved more accurate than classical filtering using principal color component (red-green-blue; RGB) for PSR detection. We applied this new method on established mouse models of liver, lung, and kidney fibrosis and demonstrated its validity by evidencing topological collagen accumulation in relevant histological compartments. Our data also showed an overall accumulation of compact fibers concomitant with worsening fibrosis and evidenced topological changes in fiber compactness proper to each model. In conclusion, we describe here a robust digital method for fibrosis analysis allowing accurate quantification, pattern recognition, and multi-organ comparisons useful to understand fibrosis dynamics.

1 August 2015 in Fertility and Sterility
Verified
Journal Article
Closed access
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
JDJacques Donnez
Jacques Donnez
EMEtienne Marbaix
Etienne Marbaix
MDMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

1 August 2018 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
JDJacques Donnez
Jacques Donnez
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
ODOlivier Donnez
Olivier Donnez
MDMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

2 January 2019 in Climacteric
Verified
Journal Article
Closed access
JDJacques Donnez
Jacques Donnez
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Uterine fibroids are the most common tumors affecting premenopausal women, responsible for bleeding, pain, and reduced quality of life. When symptomatic, their management mainly involves surgery, which is all too often radical (hysterectomy). While surgical options sparing the uterus (hysteroscopic and laparoscopic myomectomy) and other non-surgical approaches do indeed exist, drug-based therapies are associated with lower costs and morbidity rates. Since progesterone is required for fibroid growth, gonadotropin agonists have been used to control bleeding and decrease fibroid volume, but they only represent a temporary remedy due to adverse events. Ulipristal acetate (UPA), a selective progesterone receptor modulator, is indicated for fibroid management. It is safe, provides fast control of bleeding, and causes sustained fibroid volume reduction in the vast majority of cases (80%). Indeed, UPA-treated fibroids shrink by a combination of inhibition of cell proliferation, stimulation of cell death, and fibrosis resorption. In the case of symptom recurrence, repeated intermittent 3-month courses of daily UPA considerably maximize the impact of treatment, sometimes resulting in complete disappearance of treated fibroids. Despite the therapeutic dose of UPA being very well tolerated, patients with liver anomalies or disorders should be excluded at screening according to European Medicines Agency–Pharmacovigilance Risk Assessment Committee (PRAC) recommendations. We therefore propose new algorithms for fibroid management in premenopausal women with symptomatic fibroids, depending on their localization, the patient’s wishes, and clinical response, while monitoring liver enzymes and bilirubin, as recommended by the PRAC, in order to minimize the risks of possible liver toxicity.

12 November 2020 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
LCLuciana Cacciottola
Luciana Cacciottola
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
TNThu Y. T. Nguyen
Thu Y. T. Nguyen
CHCamille Hossay
Camille Hossay
JDJacques Donnez
Jacques Donnez
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans

1 February 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
PHPatrick Henriet
Patrick Henriet
EMEtienne Marbaix
Etienne Marbaix
MCMatthieu de Codt
Matthieu de Codt
MLMathieu Luyckx
Mathieu Luyckx
Marie-Madeleine DolmansMarie-Madeleine Dolmans
Marie-Madeleine Dolmans
Context: Ulipristal acetate (UPA), a selective progesterone receptor modulator, clinically reduces uterine myoma size in 80% of cases. However, the molecular mechanism of action is still poorly understood, as is the reason why 20% of myomas do not respond to treatment.Objective: To elucidate whether matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are associated with myoma volume shrinkage after UPA therapy.Design: Prospective study.Setting: Academic research unit of a university hospital.Patients: Uterine biopsies were obtained from 59 patients with symptomatic myomas undergoing myomectomy, 45 of whom were treated preoperatively with either one or greater than or equal to two, 3-month courses of UPA and 14 not given any hormone therapy to serve as controls. Myoma volume was individually monitored during UPA therapy to determine any substantial clinical response (defined as a reduction in volume of >25%). Three groups were established based on the response to treatment: responsive (R) after one course (n = 12); R after two to four courses (n = 15); and nonresponsive (NR; n = 18).Interventions: UPA treatment given as preoperative management for symptomatic myomas.Main Outcome Measures: MMP and TIMP expression assessed by zymography and immunohistochemistry.Results: Compared with controls and NR myomas, responders showed significantly higher expression levels for MMP-1 (P < 0.0001) and MMP-2 (P = 0.009) and significantly lower expression levels for TIMP-1 (P = 0.040).Conclusions: The correlation found between MMP expression and volume fold change supports the notion that MMPs play a key role in UPA-induced myoma shrinkage.